Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allyl Isothiocyanate · 1 trial · 1 indication
DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. The mean DBF in the ROI will be reported.
AUC0-20 is defined as the area under the curve from time 0-20 minutes. DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. AUC0-20 of mean DBF in ROI will be reported.
AUC0-60 is defined as the area under the curve from time 0-60 minutes. DBF is defined as the local changes in the skin blood flow after application of study intervention. DBF will be measured via a Laser Speckle Contrast Imager. AUC0-60 of mean DBF in ROI will be reported.
| Arm | Type | Description |
|---|---|---|
| Laser Speckle Contrast Imaging | EXPERIMENTAL | Participants receive topical Allyl Isothiocyanate (AITC) application and intradermal capsaicin application sequentially along with a placebo comparator (vehicle for AITC and vehicle for capsaicin) once every 2 weeks per protocol to perform laser speckle contrast imaging. |
| Name | Type | Description |
|---|---|---|
| Allyl Isothiocyanate (AITC) | DRUG | Topical administration |
| Capsaicin | DRUG | Intradermal administration |
| Vehicle for AITC | OTHER | Topical administration |
| Vehicle for Capsaicin | OTHER | Intradermal administration |
Inclusion Criteria: * Is in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms performed before randomization * Has a skin surface without significant skin allergies, pigmentary disorders or active dermatological conditions that may interfere...
Allyl Isothiocyanate is an investigational small molecule being studied in healthy participants. It is being evaluated in a Phase 1 clinical trial to assess changes in chemical agent-induced skin blood flow using laser speckle contrast imaging. The study is completed and enrolled 12 healthy male volunteers in Belgium.
Allyl Isothiocyanate is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational small molecule in healthy participants.
Allyl Isothiocyanate is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in healthy participants. The single Phase 1 trial has been completed.
Allyl Isothiocyanate has one completed Phase 1 clinical trial, identified as NCT06809569. The study, titled "A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)," enrolled 12 healthy male participants in Belgium.
Allyl Isothiocyanate is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The completed trial in healthy participants is part of early-stage research, and the drug has not yet been evaluated for any disease indication.